Opicinumab

Drug Profile

Opicinumab

Alternative Names: Anti-LINGO-1; Anti-LINGO-1 antibody; BIIB-033

Latest Information Update: 01 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biogen Idec; Dyax
  • Developer Biogen
  • Class Antibodies; Monoclonal antibodies; Neuropsychotherapeutics
  • Mechanism of Action Cell differentiation stimulants; LINGO-1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Optic neuritis

Most Recent Events

  • 24 Jul 2017 Biogen plans a phase II trial for Multiple sclerosis (Adjunctive treatment) (NCT03222973)
  • 22 Apr 2017 Updated efficacy data from the phase II SYNERGY trial in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 22 Apr 2017 Adverse events data from the phase II SYNERGY trial in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top